

1 **Express yourself: Quantitative real-time PCR assays for rapid chromosomal antimicrobial**
2 **resistance detection in *Pseudomonas aeruginosa***

3 Danielle E. Madden^{1,2}, Olusola Olagoke^{1,2}, Timothy Baird^{2,3}, Jane Neill^{2,3}, Kay A. Ramsay⁴, Tamioka A.
4 Fraser^{1,2}, Scott C. Bell^{4,5,6}, Derek S. Sarovich^{1,2*}, and Erin P. Price^{1,2*}

5 ¹Centre for Bioinnovation, University of the Sunshine Coast, Sippy Downs, Queensland, Australia

6 ²Sunshine Coast Health Institute, Birtinya, Queensland, Australia

7 ³Respiratory Department, Sunshine Coast University Hospital, Birtinya, Queensland, Australia

8 ⁴Child Health Research Centre, The University of Queensland, South Brisbane, Queensland, Australia

9 ⁵Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Chermside, Queensland, Australia

10 ⁶Translational Research Institute, Woolloongabba, Queensland, Australia

11 Keywords: Antibiotic, AMR, gene expression, *Pseudomonas aeruginosa*, efflux pumps, qPCR, *ampC*,
12 genomics

13 Running title: Assays for rapid AMR detection in *P. aeruginosa*

14 *These authors contributed equally

15 Corresponding authors:

16 Derek Sarovich, dsarovich@usc.edu.au Ph: +61 7 5456 3748

17 Erin Price, eprice@usc.edu.au Ph: +61 7 5456 5568

18 **Abstract**

19 The rise of antimicrobial-resistant (AMR) bacteria is a global health emergency. One critical facet in
20 tackling this epidemic is more rapid AMR diagnosis in serious multi-drug resistant pathogens like
21 *Pseudomonas aeruginosa*. Here, we designed and then validated two multiplex quantitative real-
22 time PCR (qPCR) assays to simultaneously detect differential expression of the resistance-
23 nodulation-division efflux pumps MexAB-OprM, MexCD-OprJ, MexEF-OprN, MexXY-OprM, the AmpC
24 β -lactamase, and the porin OprD, which are commonly associated with chromosomally-encoded
25 AMR. Next, qPCRs were tested on 15 sputa from 11 participants with *P. aeruginosa* respiratory
26 infections to determine AMR profiles *in vivo*. We confirm multiplex qPCR testing feasibility directly
27 on sputa, representing a key advancement in *in vivo* AMR diagnosis. Notably, comparison of sputa
28 with their derived isolates grown in Luria-Bertani broth ($\pm 2.5\%$ NaCl) or a 5-antibiotic cocktail
29 showed marked expression differences, illustrating the difficulty in replicating *in vivo* expression
30 profiles *in vitro*. Cystic fibrosis sputa showed significantly reduced *mexE* and *mexY* expression when
31 compared with chronic obstructive pulmonary disease sputa, despite harbouring fluoroquinolone-
32 and aminoglycoside-resistant strains, indicating that these loci are not contributing to AMR *in vivo*.
33 *oprD* was also significantly downregulated in cystic fibrosis sputa, even in the absence of
34 contemporaneous carbapenem use, suggesting a common adaptive trait in chronic infections that
35 may affect carbapenem efficacy. Sputum *ampC* expression was highest in participants receiving
36 carbapenems (6.7-15x), some of whom were simultaneously receiving cephalosporins, the latter of
37 which would be rendered ineffective by the upregulated *ampC*. Our qPCR assays provide valuable
38 insights into the *P. aeruginosa* resistome, and their use on clinical specimens will permit timely
39 treatment alterations that will improve patient outcomes and antimicrobial stewardship measures.

40 Introduction

41 The persistent rise in the prevalence and dissemination of antimicrobial-resistant (AMR) bacteria
42 threatens to push humankind towards a post-antibiotic world (1) where untreatable superbugs
43 endanger global health and food security and cause significant morbidity, mortality and economic
44 burden (2). The opportunistic Gram-negative bacterium, *Pseudomonas aeruginosa*, is a member of
45 the 'ESKAPE' group of AMR pathogens that represent the greatest concern to global health (3). *P.*
46 *aeruginosa* can cause life-threatening infections (4), including in those with chronic respiratory
47 diseases where localised immune defences are compromised such as cystic fibrosis (CF) or chronic
48 obstructive pulmonary disease (COPD) (5). Once infection is established, *P. aeruginosa* eradication is
49 made more difficult by many factors, including its high intrinsic AMR and its capacity to develop
50 multi-drug resistance (MDR) to all classes of clinically-relevant antibiotics (6).

51 AMR diagnostics are a critical weapon in our battle against superbugs as they enable rapid, cost-
52 effective, and high-throughput AMR detection, leading to more judicious and targeted antibiotic use
53 (7). However, a lack of such diagnostics means that broad-spectrum antimicrobials are commonly
54 used in the clinic in lieu of personalised treatments guided by antimicrobial sensitivity, genotype,
55 and gene expression data (8). This practice, exacerbated during the COVID-19 pandemic (9), has
56 unfortunately contributed to the emergence, persistence, and spread of AMR and MDR pathogens
57 worldwide, with potentially devastating outcomes including treatment failure and mortality (10).
58 Advancements in next-generation sequencing (NGS) technologies are enabling close-to-real-time
59 identification of AMR (11). However, it is currently impractical and costly to use these technologies
60 for rapid, high-throughput detection (12); as such, their implementation in routine clinical
61 diagnostics is not yet feasible. Instead, nucleic acid-based detection platforms such as real-time PCR
62 remain vital – and substantially cheaper, simpler, and more accessible in routine clinical
63 microbiology services than NGS – for the rapid identification of pathogens and their AMR
64 determinants (12). In addition to identifying AMR-conferring single-nucleotide polymorphisms

65 [SNPs] (13, 14), insertions/deletions (15), copy-number variants (16), gene gain (17, 18), or gene loss
66 (19), targeting altered RNA expression of key AMR loci (20-23) provides a rapid way to identify the
67 phenotypic consequences of the myriad genotypic variants that underpin AMR. For example, a
68 quantitative real-time PCR (qPCR) targeting upregulation of three key AMR resistance-nodulation-
69 division (RND) efflux pumps in the melioidosis pathogen, *Burkholderia pseudomallei*, enables the
70 simultaneous identification of meropenem (MEM) resistance, and decreased susceptibility towards
71 doxycycline and co-trimoxazole, in a single reaction (24).

72 Due to the large number of genetic mutations that can confer AMR in *P. aeruginosa* (25, 26), it
73 remains impractical to target each individual variant using PCR. Fortunately, most clinically-relevant
74 AMR in *P. aeruginosa* is thought to be conferred by a handful of key mechanisms, some of which
75 alter gene expression to drive the AMR phenotype (25). The primary AMR-conferring mutations in *P.*
76 *aeruginosa* include those that cause: i) *oprD* inactivation or repression, which commonly leads to
77 carbapenem resistance (27, 28); ii) *ampC* hyper-production, a predominant cause of β -lactam AMR
78 (25); iii) DNA gyrase A (*gyrA*) alteration, associated with fluoroquinolone (FQ) AMR (13, 29); and iv)
79 upregulation of one or more RND efflux pumps, leading to AMR or MDR (23). The most important
80 AMR-conferring RND efflux pumps in *P. aeruginosa* are MexAB-OprM (30) (FQs, β -lactams including
81 carbapenems (31), and β -lactam inhibitors (25)), MexEF-OprN (FQs) (32), MexXY (33)
82 (aminoglycosides and FQs (34)), and MexCD-OprJ (35) (FQs (36) and some fourth-generation
83 cephalosporins (37)).

84 Whilst PCR assays exist to individually detect differential gene expression of *ampC* (20, 26, 34), *mexB*
85 (22, 38), *mexX* (20, 39), *mexY*, *mexD*, *mexF* (22, 23), *mexA* and *oprD* (22, 34, 39) in *P. aeruginosa*,
86 none simultaneously detect expression of these genes. In addition, nearly all *P. aeruginosa* AMR
87 gene expression studies to date have assessed lab-cultured isolates (23, 38); with only one published
88 study assessing AMR gene expression *in vivo*, whereby singleplex assays were used to detect *ampC*

89 and *mexX* expression in 31 CF sputa, followed by comparison with corresponding derived isolates
90 (20).

91 To address these knowledge gaps, we developed and validated two multiplex qPCR assays to
92 simultaneously detect altered expression of six key genes that confer AMR towards most clinically-
93 relevant antibiotic classes, using *rpsL* as an internal reference gene for expression normalisation.
94 qPCRs were initially tested in cultures, and subsequently directly on 15 sputa, to permit *in vivo P.*
95 *aeruginosa* gene expression characterisation (20), thus removing transcriptional biases introduced
96 by culturing. qPCR results were also correlated with current anti-pseudomonal treatment to
97 determine the impact of antibiotic therapy on *in vivo* AMR gene expression, along with strain
98 phenotype and predicted *in silico* AMR genotype data.

99 **Methods**

100 **Ethics statement and participant recruitment.** This study was approved by The Prince Charles
101 Hospital (TPCH) Human Research Ethics Committee, project IDs HREC/13/QPCH/127 (CF) and
102 HREC/2019/QPCH/48013 (COPD). Site-specific approvals were obtained for CF recruitment at TPCH,
103 Brisbane, Australia, and COPD recruitment at Sunshine Coast Hospital and Health Service, Sunshine
104 Coast, Australia. CF sputa were collected from participants with chronic *P. aeruginosa* infection who
105 were admitted to the Cystic Fibrosis Centre at TPCH for intravenous antibiotic therapy; COPD sputa
106 was collected from participants either admitted to Sunshine Coast University Hospital (SCUH) for
107 pulmonary exacerbations, or whose symptoms were being managed at home as part of the
108 Respiratory Acute Discharge Service program; whether they had acute or chronic *P. aeruginosa*
109 infection was not known. All participants provided written consent.

110 **Total RNA extraction and microbial RNA enrichment from sputa.** Nine sputa from five CF
111 participants, and six sputa from six COPD participants (40) (Table 1), all with high-load *P. aeruginosa*
112 infections according to sputum culture onto MacConkey agar (Oxoid, Heidelberg West, VIC,
113 Australia), were subjected to total RNA extraction to determine *in vivo* *P. aeruginosa* AMR gene
114 expression profiles. An additional six sputa from *P. aeruginosa*-infected COPD participants with low
115 *P. aeruginosa* load were also examined, along with three COPD sputa and 1 COPD bronchial washing
116 from *P. aeruginosa* culture-negative participants. Sputa were collected directly into RNA stabilisation
117 reagent (10mM EDTA, 25mM sodium citrate, 700g/L ammonium sulphate; pH=5.2; Sigma-Aldrich,
118 Castle Hill, NSW, Australia) to immediately halt transcriptional activity, and kept at 4°C until RNA
119 extraction (up to ~1 month). Between 30 µL and 1 mL sputum was placed into 0.5-6 mL TRI Reagent
120 LS (Sigma) and 30-240 µL 2-mercaptoethanol (Sigma) aliquoted into sterile, RNase-free 2 mL O-ring
121 tubes (SSIBio, Lodi, CA, USA) containing ~100 µL equal mixture of 0.1 and 0.5 mm zirconia beads
122 (Daintree Scientific, St Helens, Tasmania, Australia). Tubes were parafilmed and subjected to four
123 rounds of bead beating at 30 sec pulses using the Minilys tissue homogeniser on the medium setting

124 (Bertin Instruments, Montigny-le-Bretonneux, France), with samples cooled on ice for >30 sec after
125 each round to minimise RNA degradation. Extracted RNA was treated with DNase Max (Qiagen),
126 confirmed DNA-free using a 16S ribosomal RNA gene PCR (41), and host RNA-depleted using
127 MICROBEnrich (Thermo Fisher Scientific, Seventeen Mile Rocks, QLD, Australia) as per
128 manufacturer's instructions. cDNA (iScript; Bio-Rad, Gladesville, NSW, Australia) was qPCR-tested at
129 neat and 1:10 concentrations.

130 **Growth conditions and antibiotic sensitivity testing.** Nineteen *P. aeruginosa* strains (12 CF, 7 COPD)
131 were isolated from sputa using MacConkey agar and incubated at 37°C for 24 h. Subcultures were
132 grown on Luria-Bertani (LB) agar (Oxoid) under the same conditions. All strains were confirmed as *P.*
133 *aeruginosa* by rapid chelex-100 (Bio-Rad) heat soak extraction (42) followed by *ecfX* real-time PCR
134 on a 1:50 dilution of the chelex supernatant (43). Susceptibility towards amikacin (AMK; 30µg),
135 cefepime (30µg), ceftazidime (CAZ; 30µg), ciprofloxacin (5µg), colistin (10µg), imipenem (10µg),
136 piperacillin (30µg), piperacillin-tazobactam (100µg/10µg), polymyxin B (300U), and tobramycin (TOB;
137 10µg) were determined by disc diffusion (Edwards Group, Murrarie, QLD, Australia); Etests were
138 used for MEM susceptibility testing (bioMérieux, Baulkham Hills, NSW, Australia). Sensitivity,
139 intermediate resistance, and AMR were determined using CLSI M100S-Ed27:2021 guidelines (Table
140 1). PAO1 (LMG 12228) was included as a wild-type reference. MDR was defined as non-susceptibility
141 to at least one antibiotic in three or more antibiotic classes (44).

142 **Growth experiments and RNA extraction.** To assess AMR gene expression levels in derived cultures,
143 a starting inoculum of 10⁵ cells was grown to late-log phase (OD₆₀₀≈1) with orbital shaking at 250 rpm
144 (Ratek Laboratory Equipment [model number OM11], Boronia, VIC, Australia) for 16 h at 37°C in
145 2mL LB broth ±2.5% NaCl. RNA was extracted using TRI Reagent (Sigma-Aldrich) and treated with
146 TURBO DNase (Thermo Fisher Scientific) according to manufacturer's instructions. 1:10-diluted DNA-
147 free RNA was converted to cDNA using iScript. cDNA was diluted 1:25 in molecular-grade H₂O prior
148 to qPCR.

149 We also attempted to induce AMR gene expression in two *P. aeruginosa* cultures, SCHI0002.S.9 and
150 SCHI0010.S.1, using sub-inhibitory concentrations (0.25 µg/mL each) of five antibiotics not used in *P.*
151 *aeruginosa* treatment but known to induce its RND efflux pumps – gentamicin for *mexX* upregulation
152 (45), novobiocin for *mexB* upregulation (31), norfloxacin for *mexC* upregulation (46),
153 chloramphenicol for *mexE* upregulation (47) and ampicillin for *ampC* upregulation (48). These strains
154 were selected as both encode MDR phenotypes; in addition, SCHI0010.S.1 encodes a high-
155 consequence frameshift mutation in MutS (R360fs), resulting in a hypermutator phenotype (49).

156 **Multiplex AMR locus qPCR assay design and PCR conditions.** To quantify *mexAB-oprM*, *mexCD-oprJ*,
157 *mexEF-OprN*, *mexXY-OprM*, *ampC*, and *oprD* expression, two multiplex assays targeting the *mexB*,
158 *mexC*, *mexE*, *mexY*, *ampC*, and *oprD* genes, respectively, were designed (Table 2). A BLAST database
159 comprising 730 *P. aeruginosa* genomes (50-54) was used to identify conserved regions for oligo
160 design. Oligo self-dimers and heterodimers were assessed and avoided as previously described (55).
161 Each PCR consisted of 1× SsoAdvanced Universal Probes Supermix (Bio-Rad), optimised primer and
162 probe concentrations (Macrogen Inc., Geumcheon-gu, Seoul, South Korea; Table 2), 1 µL genomic
163 DNA (gDNA) or cDNA template, and PCR-grade H₂O, to 5 µL. Isolate gDNA/cDNA thermocycling
164 comprised enzyme activation at 95°C for 2 min, followed by a 2-step program (95°C for 5 sec and
165 60°C for 15 sec) for 45 cycles; for sputum cDNA, a 3-step program (95°C for 5 sec, 60°C for 15 sec,
166 and 72°C for 15 sec) for 45 cycles was used to enhance *P. aeruginosa* detection from polymicrobial
167 DNA.

168 **qPCR assay limits of detection (LoD) and quantification (LoQ).** LoD and LoQ values were determined
169 for each assay when in multiplex format using 1:10 serial dilutions of SCHI0005.S.10 *P. aeruginosa*
170 genomic DNA ranging from 40 to 4 × 10⁻⁶ ng across eight replicates, as previously described (56, 57).
171 Genome equivalents (GEs) were calculated based on the average PAO1 genome size of 6.22Mbp and
172 a single copy of each gene. For all assays, all samples were run in duplicate, and at least two no-
173 template controls were included in each run.

174 **qPCR normalisation and analysis.** The constitutively expressed *rpsL* gene (Table S1) was used to
175 normalise AMR gene expression via the difference in cycles-to-threshold (ΔC_T) method (34, 58). After
176 *rpsL* normalisation, ΔC_T values were further normalised against either PAO1 expression, or to
177 SCHI0070_D2 COPD sputum ($\Delta\Delta C_T$), the latter of which enabled gene expression comparison among
178 sputa, and between sputa and derived isolates. SCHI0070_D2 COPD sputum was chosen for
179 normalisation as this participant had no recent history of anti-pseudomonal antibiotic treatment, its
180 derived isolate, SCHI0070.S.1, was sensitive towards all 11 anti-pseudomonal antibiotics (Table 1),
181 and there was good gene expression across all seven loci for this sample, thus enabling relative
182 expression profiling of qPCR-tested genes across all tested sputa. For AMR loci lacking detectable
183 PCR amplification, a C_T value of 45 was assigned to permit visualisation of genes with very low/no
184 expression. According to previously defined criteria (23), strains were regarded as hyper-producers if
185 their AMR loci exhibited >10-fold higher expression compared with PAO1, except for *mexB* and
186 *mexY*, which were considered hyper-producing if >3-fold higher expression than PAO1 (23, 34, 38).

187 **Strain genome sequencing.** The genomes of 14 strains have been previously published (13); paired-
188 end Illumina genomes for SCHI0065.S.1 and SCHI0070.S.1 were generated in the current study and
189 appended to NCBI BioProject PRJNA761496. We did not sequence SCHI0018.S.11, SCHI0038.S.2, or
190 SCHI0038.S.4 as these data were not considered essential for study outcomes.

191 **Culturome sequencing and *P. aeruginosa* mixture analysis.** Culturomes for SCHI0002_D8,
192 SCHI0002_D329, SCHI0010_D7, SCHI0013_D4, SCHI0038, SCHI0039, and SCHI0050_D3 were
193 generated from Chocolate agar culture sweeps. Microbial cells were lysed with 250 U/mL
194 mutanolysin, 22 U/mL lysostaphin, and 20mg/mL lysozyme, followed by DNA extraction using the
195 Qiagen DNeasy Blood and Tissue kit 'Pretreatment for Gram-Positive Bacteria' protocol. Culturomic
196 data were Illumina paired-end sequenced at the Australian Genome Research Facility (Melbourne,
197 VIC, Australia) or Ramaciotti Centre for Genomics (Sydney, NSW, Australia) to obtain a minimum of 7
198 million reads. The culturomic sequence data are available under NCBI BioProject PRJNA761496.

199 *P. aeruginosa* mixtures were assessed by mapping reads to PAO1 (GenBank: CP053028.1) with
200 ARDaP v1.9 (59) (<https://github.com/dsarov/ARDaP>) using the --mixtures flag. Heterogeneous
201 variant sites were then identified and counted from each sample's variant call file (.vcf) based on
202 '0/1' in the 'GT' (genotype) field.

203 **AMR prediction from genomes and culturomes.** *In silico* AMR prediction for 16 genome-sequenced
204 isolates, PAO1 (Table 1), and the sputum culturomic data was carried out using the *P. aeruginosa*-
205 specific database in ARDaP. Prior to ARDaP analysis, *Pseudomonas* (taxid: 286) and *P. aeruginosa*
206 (taxid: 287) specific reads were extracted from the raw culturomic data using Kraken 2 (60) to
207 classify reads followed by sektq (<https://github.com/lh3/seqtk>) for retrieval, with resultant coverage
208 ranging from 21x to 43x (calculated using Mosdepth (61)). For culturomic analysis, ARDaP was again
209 run in mixture mode (--mixtures flag), with the ResFinder (62) component disabled due to the
210 presence of multiple species.

211 **Statistical analysis.** Gene expression differences were assessed using a two-way analysis of variance
212 test and Tukey's multiple comparison test using GraphPad Prism (GraphPad Software Inc., CA, USA).
213 Corrected *p* values of <0.05 were considered significant.

214 Results

215 **Multiplex qPCR assay performance.** To assess assay sensitivity, LoD and LoQ values were
216 determined using a 10-fold DNA dilution series (40 ng to 0.04 fg). The LoD for all assays was 400 fg
217 (59 GEs), the LoQ for *mexB*, *mexE* and *mexC* was 400fg (59 GEs), and the LoQ for *rpsL*, *ampC*, *mexY*
218 and *oprD* was 4000 fg (587 GEs) (Figures S1 and S2). Based on these results, an *rpsL* $C_T < 30$ was
219 identified as the upper threshold for accurately assessing gene expression of AMR loci.

220 **Antibiotic susceptibility profiles.** Testing towards 11 anti-pseudomonal antibiotics identified much
221 higher rates of AMR (range: 0-9 antibiotics) and MDR (10/12 strains) in CF-derived isolates when
222 compared with COPD-derived isolates (range: 0-2 antibiotics; 0/7 MDR strains) (Table 1). This was
223 consistent with much greater antibiotic use in the CF cohort (Table 1) (40). The lowest susceptibility
224 rates were towards cefepime (0% CF and 100% COPD) and piperacillin (33% CF and 100% COPD),
225 whereas all 19 strains were susceptible to colistin and polymyxin B (Table 1). Interestingly, cefepime
226 is rarely used for CF treatment at TPCH, indicating probable cross-resistance towards this antibiotic
227 in all CF-derived isolates. None of the participants were receiving polymyxins; as such, no AMR was
228 expected towards these antibiotics.

229 **In silico AMR prediction in isolate genomes.** Genomic analysis of the derived *P. aeruginosa* isolates
230 revealed a much greater number of AMR determinants in the CF-derived strains (Table 1). Although
231 some AMR determinants were identified in COPD isolates, only one was associated with
232 dysregulated expression of the six AMR loci. In contrast, many CF-derived isolates encoded
233 mutations predicted to alter gene expression of our qPCR gene targets (Table 1). Specifically, *ampC*
234 overexpression was predicted in SCHI0030.S.2 and SCHI0030.S.3 due to AmpD regulator loss (P42fs)
235 (63), and a non-inducible *ampC* phenotype was predicted in SCHI0038.S.3 due to a E592fs nonsense
236 mutation in AmpG (64); *mexAB-oprM* overexpression was predicted in SCHI0002.S.9 and
237 SCHI0002.S.12 due to a D187H missense mutation in the NalD regulator (65); and *mexCD-oprJ*
238 overexpression was predicted in SCHI0030.S.4 due to NfxB regulator loss (F126fs) (66). No mutations

239 associated with *mexEF-oprN* or *mexXY-oprM* overexpression were identified. Although not
240 associated with gene expression changes, *oprD* loss was predicted in SCHI0002.S.8 (W339Ter) and
241 SCHI0030.S.3 (G193fs), which is linked to carbapenem resistance, especially when associated with
242 *ampC* upregulation (25, 67) as observed in SCHI0030.S.3.

243 Other AMR determinants were identified in our strain dataset, including multiple determinants
244 encoding decreased susceptibility or AMR towards CIP (GyrA T83I, D87H or D87N, GyrB S466F and
245 ParE A473V (68)) (Table 1). In addition, an R504C missense variant in FtsI, known to confer resistance
246 to β -lactams (69), was detected in three CF-derived, multi- β -lactam-resistant isolates (SCHI0002.S.8,
247 SCHI0030.S.2, and SCHI0030.S.3), and a FusA1 missense mutation, A555E (70), was identified in CF-
248 derived isolate SCHI0010.S.1 (AMK- and TOB-resistant) (Table 1). Finally, MexEF-OprN loss was
249 predicted in SCHI0013.S.2 and SCHI0013.S.12 due to a frameshift (R229fs) in the MexE membrane
250 fusion protein, and in SCHI0030.S.2 and SCHI0030.S.3 due to the introduction of a stop codon
251 (Y37Ter) in the MexF multidrug inner membrane transporter (71). Unlike the AMR variants, these
252 *mexE* and *mexF* mutations render the MexEF-OprN pump inoperable, and thus unable to contribute
253 towards AMR, irrespective of *mexEF-oprN* upregulation.

254 ***In silico* AMR prediction in culturomes.** Mixed variant site analysis (Table S2) of culturomic data
255 identified multiple *P. aeruginosa* strains in 1/4 CF and 0/3 COPD sputa. The SCHI0002_D8 culturome
256 had a high number of mixed variant sites (21664 variants), confirming that ≥ 2 genetically distinct
257 strains were present; in contrast, multiple strains were not detected in the SCHI0002_D329,
258 SCHI0010_D7, SCHI0013_D4, SCHI0038, SCHI0039, or SCHI0050_D3 sputa (833, 1521, 701, 1039,
259 688, 678 variants, respectively) when compared with mixed variant site analysis in clonal, derived
260 strains (Table S2).

261 ARDaP AMR prediction (Table 1) identified AMR determinants not retrieved during single-strain
262 culturing in 3/7 culturomes (3/4 CF and 0/3 COPD sputa). GyrB E483D (72) and ParC S87W (73),
263 known to contribute to ciprofloxacin resistance, were identified in SCHI0002_D8 at a frequency of

264 8% and 10%, respectively; further, this sample had minor components of the AMR determinants
265 FdnH V215fs (12%), PA1259 F273fs (38%), PA2198 R33fs (11%), and PepA E363fs (14%), all of which
266 cause decreased piperacillin susceptibility (74). A FtsI H394R missense mutation (75) was identified
267 in SCHI0010 at 61% prevalence, and in SCHI0013, a W6Ter nonsense mutation caused by a G→A
268 transition was identified in OprD at 22% prevalence, predicted to cause carbapenem resistance,
269 along with PA3093 loss (15%), associated with intermediate piperacillin resistance (Table 1).
270 Importantly, no additional mutations were identified that were predicted to alter expression of the
271 six AMR loci. Further, the culturomic data did not detect some AMR determinants found in the
272 single-isolate data (Table 1).

273 **Comparison of AMR variant prediction with *in vitro* AMR gene expression.** Relative AMR gene
274 expression in derived *P. isolates* grown in LB broth ($n=15$; Figure S3), LB+NaCl ($n=14$; Figure S4), or a
275 5-antibiotic cocktail ($n=2$; Figure S5) was assessed. All qPCR targets exhibited expression in at least
276 one strain; however, in some strains, particularly the CF-derived isolates, certain genes exhibited no
277 expression (Figures S3-S5). Just two loci were expressed in all tested strains across all conditions: the
278 housekeeping gene *rpsL* ($C_T=25.3\pm 1.97$) and *mexB* ($C_T=29.0\pm 2.14$). *oprD* was expressed in all strains
279 except SCHI0039.S.1 grown in LB+NaCl. In contrast, *ampC*, and *mexC*, *mexE*, and *mexY* were
280 expressed in 1, 23, 26, and 2 of the 31 tested strains, respectively. Genetic analysis of all qPCR-
281 targeted loci confirmed 100% primer and probe matches in those strains with genomic data, thereby
282 ruling out assay failure as a cause of undetectable expression.

283 Unexpectedly, there was no concordance between *in silico* AMR predictions and qPCR results for
284 strains grown under any of the tested conditions. SCHI0030.S.2 and SCHI0030.S.3, which were
285 predicted to upregulate *ampC* through a previously undocumented AmpD frameshift variant (P42fs),
286 exhibited negligible or no *ampC* expression when grown in LB broth or LB+NaCl (Figures S3 and S4).
287 In contrast, SCHI0010.S.1, which does not encode any known chromosomal variant associated with
288 *ampC* upregulation (Table 1), demonstrated *ampC* hyper-expression (43x) in LB broth relative to

289 PAO1, although no detectable *ampC* expression under salt (Figure S2) or antibiotic stress (Figure S3).
290 Similarly, SCHI0002.S.9 and SCHI0002.S.12 failed to overexpress *mexB*, and, surprisingly,
291 SCHI0030.S.4 failed to overexpress *mexC*, despite predicted upregulation. Once again, SCHI0010.S.1
292 grown in LB, but not in LB+NaCl, unexpectedly hyper-expressed *mexB* (19x), *mexC* (19x), *mexE* (24x),
293 and *mexY* (16x) in lieu of encoding any known variants associated with upregulation of these loci. No
294 other strain tested under any condition upregulated *mexB*, *mexC*, *mexE*, or *mexY*. Although no
295 strains were predicted to exhibit *oprD* downregulation, *oprD* was not expressed in SCHI0039.S.1
296 grown in LB±NaCl, and was significantly downregulated in SCHI0010.S.1 grown in LB+NaCl (Figures S3
297 and S4). All other strains exhibited good *oprD* expression, including SCHI0002.S.8 and SCHI0030.S.3;
298 although these strains encode truncated OprD, these deleterious mutations occur downstream of
299 the oligo-binding sites, and are therefore undetected by our assay.

300 **AMR gene expression in sputa.** All COPD sputa yielded more similar expression profiles to the
301 SCHI0070_D2 COPD control than any of the nine CF sputa (Figure 1). The only overexpressed loci in
302 the CF or COPD sputa were: *ampC* (4/9 CF [1.7-15.1x] and 2/5 COPD [1.7-3.5x]), *mexB* (3/5 COPD
303 [1.5-2.5x]), *mexC* (2/9 CF [1.7-2.1x] and 2/5 COPD [6.4x each]), *mexY* (4/5 COPD [1.8-7.3x]), and *oprD*
304 (3/5 COPD [1.7-51x]) (Figure 2). All CF sputa exhibited downregulation or no expression of *mexB*
305 ($\geq 4.0x$), *mexE* ($\geq 3.9x$), *mexY* ($\geq 5.2x$), and *oprD* ($\geq 377x$), and 6/9 were downregulated or had no
306 detectable expression for *mexC* ($\geq 3.4x$). When comparing CF and COPD sputum expression, no
307 significant difference was observed for *ampC*, *mexB*, or *mexC*; in contrast, *mexE*, *mexY*, and *oprD*
308 were all significantly downregulated in CF sputa (Figure 1).

309 Correlation of qPCR results with antibiotic treatment (Table 1) identified that sputum *ampC*
310 expression levels were a good indicator of current β -lactam use, with 4/5 sputa with elevated *ampC*
311 expression collected from participants contemporaneously receiving β -lactams (SCHI0002_D8,
312 SCHI0010_D7, SCHI0013_D4, and SCHI0018_D8). Notably, 2/3 sputa (SCHI0002_D8 and
313 SCHI0013_D4) obtained from participants being treated with MEM, either with or without CAZ,

314 overexpressed *ampC* at high levels (6.7-15x); in contrast, *ampC* expression was only moderately
315 upregulated (1.7-1.9x) in two sputa (SCH10010_D7 and SCH10018_D8) from participants on CAZ but
316 not MEM (Table 1; Figure 2). *ampC* was downregulated or not expressed in eight sputa (Figure 2) - of
317 these, four were collected from participants receiving no antibiotics at the time of collection, three
318 were receiving antibiotics other than β -lactams, and just one (SCH10002_D329) was receiving CAZ
319 and MEM at the time of sputum collection (Table 1).

320 **AMR gene expression between sputa and *in vitro* cultures.** Sputum AMR gene expression was
321 compared with derived cultures grown in LB broth (Figure S3), LB+NaCl (Figure S4), and a 5-antibiotic
322 cocktail (Figure S5) to determine whether culture AMR gene expression was reflective of *in vivo*
323 conditions. Overall, there was very poor concordance between *in vivo* and *in vitro* expression
324 profiles across all tested *in vitro* conditions, with most loci exhibiting dissimilar expression between
325 derived isolates and their corresponding sputa. Most striking was *oprD*, which, in most cases, was
326 upregulated in strains grown under the three *in vitro* conditions (Figures S3-S5) yet largely
327 downregulated *in vivo* (Figure 2).

328 **RND efflux pump expression during antibiotic treatment.** The four longitudinal sputa collected from
329 SCH10030, who received intravenous TOB and aztreonam for 15 days, provides an interesting case
330 study for observing AMR gene expression dynamics before, during, and after antibiotic treatment
331 (Table 1). Although TOB has previously been shown to induce MexXY-OprM expression in CF sputa
332 (20), we unexpectedly did not observe AMR gene expression changes in SCH10030 sputa (Figure 2).
333 Five sputa from other CF participants also showed limited or no *mexY* expression. In comparison,
334 *mexY* was significantly upregulated in 4/5 COPD sputa (Figure 2), none of whom have ever received
335 TOB (Table 1).

336 Discussion

337 Here, we developed and validated two multiplex qPCR assays for the simultaneous detection of
338 altered AMR locus expression in the ESKAPE pathogen, *P. aeruginosa*. When run in multiplex format,
339 our qPCRs showed very good to excellent LoD and LoQ values. qPCRs can be used both on *P.*
340 *aeruginosa* cultures and directly on human RNA-depleted sputa, the latter of which provides *in vivo*
341 expression profiling that overcomes transcriptional bias introduced with *in vitro* culture (20).
342 Building upon the pioneering work of Martin and colleagues, who first reported limited correlation
343 in *ampC* and *mexX* expression between sputa and corresponding derived isolates (20), we also
344 observed poor concordance between *in vivo* and *in vitro* expression profiles across six tested AMR
345 loci. Further, we found surprisingly poor correlation between *in silico*-predicted and *in vitro* AMR
346 gene expression. These findings raise questions about the clinical utility of *in vitro* antimicrobial gene
347 expression profiling and highlight the need for more work in this critical area of AMR research.

348 **AmpC-driven AMR.** We found that sputum *ampC* expression correlated well with contemporaneous
349 β -lactam treatment. In particular, two CF participants (SCH10010 and SCH10018) receiving CAZ but no
350 other β -lactams overexpressed *ampC* at moderate levels (1.7-2x); this overexpression increased to
351 6.7-15x in two other participants (SCH10002 and SCH10013) receiving MEM (Table 1; Figure 2).
352 Carbapenems such as MEM can be potent *ampC* inducers (67) and can remain effective even when
353 *ampC* expression is elevated (25), whereas cephalosporins such as CAZ are relatively weak inducers
354 of *ampC* and are readily hydrolysed by this enzyme (25). Our findings confirm that MEM can act as a
355 strong inducer of *ampC* expression *in vivo*. In light of this, we recommend that *P. aeruginosa*
356 infections should not simultaneously be treated with carbapenems and cephalosporins due to
357 potential *ampC* induction, which would render cephalosporin (and likely other β -lactam) antibiotics
358 ineffective (25). In contrast, eight sputa exhibited downregulated or no *ampC* expression (Figure 2),
359 seven of which were taken from participants either not on antibiotics or not receiving β -lactams at
360 the time of sample collection, which likely explains the lack of β -lactam-driven *ampC* selection

361 pressure. Of note, two COPD sputa, SCHI0109 and SCHI0050_D3, showed *ampC* upregulation (1.7-
362 3.5x), despite neither participant receiving contemporaneous β -lactam therapy. Whilst the basis for
363 this upregulation is unknown, we speculate that β -lactam use in these participants would be
364 ineffective for *P. aeruginosa* eradication. Taken together, our results demonstrate that routine *ampC*
365 qPCR testing of *P. aeruginosa*-positive specimens is a useful diagnostic for monitoring *in vivo*
366 cephalosporin efficacy, enabling more rapid treatment shifts in instances where *ampC* is
367 upregulated.

368 Unlike sputa, almost all derived isolates failed to express *ampC* when grown in three different liquid
369 media. The exception was the derived isolate from CF participant SCHI0010. In LB broth,
370 SCHI0010.S.1 exhibited *ampC* hyper-expression (15x relative to SCHI0070_D2, and 43x relative to
371 PAO1; Figure S3), yet the corresponding sputum showed only modest *ampC* upregulation (1.7x;
372 Figure 2). This finding was unexpected as SCHI0010.S.1 does not encode any known chromosomal
373 variant associated with *ampC* upregulation (Table 1), and did not overexpress *ampC* when grown in
374 LB+NaCl or the 5-antibiotic cocktail (Figures S4-S5). These results indicate that SCHI0010.S.1 encodes
375 an enigmatic determinant for upregulating *ampC* expression when grown under particular
376 conditions. Whilst the basis of this overexpression requires further investigation, we postulate that it
377 may be driven by global transcriptional regulator inactivation due to its hypermutator status,
378 resulting in marked transcriptome differences affecting multiple gene pathways. In contrast, strains
379 SCHI0030.S.2 and SCHI0030.S.3, both predicted to upregulate *ampC* due to a truncated AmpD,
380 exhibited negligible or no *ampC* expression *in vitro* (Figures S3-S4). This result correlated with the
381 longitudinal SCHI0030 sputa, all of which exhibited significantly downregulated *ampC* expression.
382 One possibility for the lack of *ampC* expression in SCHI0030 is that the AmpD P42fs mutation may
383 only confer a partially de-repressed *ampC* phenotype (26); another possibility is that additional
384 chromosomal determinants, such as those occurring in other AmpD homologues (26) or DacB (76),
385 may be required to confer *ampC* upregulation (63) in AmpD P42fs-encoding strains.

386 Expression of *ampC* was also undetectable in the MDR strain, SCHI0002.S.9, across the three *in vitro*
387 conditions (Figures S3-S4). Whilst this observation is consistent with the lack of predicted *ampC*
388 dysregulation in the SCHI0002.S.9 genome, it does not reflect the AMR phenotype of this strain,
389 which was resistant to all six tested penicillin, cephalosporin, and carbapenem antibiotics (Table 1).
390 In addition, the corresponding SCHI0002_D8 sputum displayed the greatest *ampC* upregulation (15x;
391 Figure 2), probably due to contemporaneous CAZ and MEM treatment (Table 1). One possible
392 explanation for these spurious results is that high sputum *ampC* levels are conferred by an un-
393 retrieved *P. aeruginosa* strain (20), as supported by two distinct AMR phenotypes and genotypes
394 isolated from SCHI0002_D8, SCHI0013_D4, and SCHI0030_D50 sputa (Table 1) and *in silico* strain
395 mixture analysis of culturomic data, which identified multiple *P. aeruginosa* strains in one CF sputum
396 sample (SCHI0002_D8) (Table S2). Indeed, phenotypic and genotypic diversity of *P. aeruginosa* is
397 well-documented in chronic CF infections (77), and increasingly, in COPD infections (78). However,
398 our culturomic mixture analysis failed to identify any additional mutations associated with altered
399 gene expression of *ampC* or the other tested AMR loci (Table 1), so it remains unconfirmed whether
400 undetected determinants are contributing to AMR. Another explanation is that *ampC* expression in
401 SCHI0002 strains may require MEM (20) or ceftiofloxacin (79) rather than ampicillin (48) for *in vitro*
402 induction, as certain antibiotics are known to be better than others for inducing *ampC* (20).
403 However, antibiotic induction only provides a crude representation of *in vivo P. aeruginosa* activity,
404 as the lung environment is exceptionally difficult to mimic *in vitro* (20, 77, 80). The lack of correlation
405 between *ampC* upregulation in sputa and derived cultures (Figures S3-S5) has also been reported in
406 a separate study (20), and emphasises the challenges in replicating *in vivo* conditions *in vitro*.

407 **Efflux-mediated AMR.** *mexB*, *mexC*, *mexE* and *mexY* represent the RND efflux pumps most
408 frequently associated with AMR and MDR in *P. aeruginosa* (23, 25). As most CF participants were
409 being treated with anti-pseudomonal antibiotics at the time of sputum collection, and many of their
410 derived isolates encode key mutations associated with altered RND efflux pump expression (Table
411 1), we expected upregulation of these four efflux pumps in CF sputa. It was therefore surprising that

412 *mexC* was the only efflux system that demonstrated modest (1.7-2.1x) upregulation in a few patients
413 (2/9 CF sputa), whereas the other RND efflux systems were largely downregulated, or switched off
414 entirely, in CF sputa (Figure 2). Also surprising was that most COPD sputa showed good expression of
415 these loci, despite only two COPD participants contemporaneously receiving anti-pseudomonal
416 antibiotics, and almost no AMR phenotypes or efflux pump expression-altering genotypes in the
417 derived COPD isolates (Table 1). This difference between diseases was most apparent for *mexE*,
418 *mexY*, and *oprD*, which were significantly downregulated in CF but not COPD sputa (Figure 1).
419 Although our dataset is small, these observations suggest that RND efflux pump expression, and
420 particularly *mexE* and *mexY* expression, may not be required for chronic *P. aeruginosa* persistence in
421 CF airways. This finding contradicts prior *in vitro* work suggesting that MexXY-OprM efflux pump
422 upregulation is necessary for *P. aeruginosa* survival in the CF lung (81). We further postulate that the
423 MexEF-OprN and MexXY-OprM RND efflux pumps may have a minimal role, if any, in conferring AMR
424 in *P. aeruginosa in vivo*. *mexE* and *mexY* qPCR testing across a larger CF and COPD sputum panel is
425 needed to determine the veracity of our findings.

426 One possible explanation for efflux pump downregulation in CF sputa is that the CF cohort all
427 harboured chronic *P. aeruginosa* infections, whereas the COPD cohort potentially only had transient
428 (i.e. acute) infections. Like virulence factors (82), RND efflux pump expression may be upregulated
429 during the acute phase but then downregulated once *P. aeruginosa* transitions to a chronic lifestyle,
430 the latter of which is characterised by biofilm formation and reduced metabolic activity (25, 83). In
431 support of this hypothesis, longitudinal sputa collected from CF participant SCHI0030 just prior,
432 during, and after a 15-day course of intravenous TOB and aztreonam treatment showed virtually no
433 change in RND efflux pump expression, with all AMR genes (including *mexY*) downregulated (Figure
434 2) despite the aminoglycoside onslaught. In addition, one of two SCHI0030 strains obtained 35 days
435 after antibiotic cessation was fully susceptible to all 11 tested antibiotics, including TOB, hinting at
436 insufficient antibiotic penetration due to biofilm. As ours is one of the few studies to investigate *P.*
437 *aeruginosa* AMR gene expression *in vivo*, and the first to assess COPD sputa, more work is required

438 to verify these hypotheses, as there remains stark limitations in our understanding of the
439 characteristics of *P. aeruginosa* infection (including AMR development), particularly in people with
440 COPD (84). Examining *in vivo* AMR gene expression dynamics over a long-term *P. aeruginosa*
441 infection would shed important information about the adaptive processes that occur during the
442 transition from acute infection to chronic persistence. We anticipate that our multiplex assays will
443 be a valuable tool for such studies.

444 Analysis of RND efflux expression among the CF-derived isolates encoding predicted RND efflux
445 upregulation revealed that almost none demonstrated increased efflux pump expression *in vitro*
446 (Figures S3-S5). Curiously, the MDR and hypermutated isolate SCH10010.S.1, which does not encode
447 any known mutations associated with RND efflux pump upregulation, exhibited *mexB* (5.3x), *mexC*
448 (1.7x), *mexE* (1.5x), and *mexY* (28x) overexpression when grown in LB, although not when grown in
449 LB+NaCl or the 5-antibiotic cocktail (Figures S3-S5). These results indicate that there are growth-
450 specific requirements associated with upregulation of these genes. Furthermore, these observations
451 collectively indicate that *in vitro* efflux pump expression is not a good proxy for AMR phenotype, as
452 our CF-derived *P. aeruginosa* isolates demonstrate extensive MDR, yet we were unable to reproduce
453 their expected gene expression alterations *in vitro*. Our results contradict other *in vitro* experiments
454 reporting RND efflux pump hyper-expression as a major contributing factor to AMR development in
455 CF airway-derived *P. aeruginosa* (34, 39). Caution should thus be taken when attempting to correlate
456 predicted AMR phenotypes with *in vitro* RND efflux pump expression profiles due to considerable
457 AMR gene expression changes exhibited under different culture conditions.

458 **OprD-mediated AMR.** As with the other AMR loci, we saw an unexpectedly poor correlation
459 between *in vitro* and *in vivo* *oprD* expression. Whereas 17/19 *in vitro* cultures expressed *oprD* at high
460 levels (Figures S3-S5), 9/9 CF and 2/5 COPD sputa exhibited no detectable *oprD* expression (Figure
461 2), and *oprD* was significantly downregulated in CF sputa (Figure 1). This finding strongly suggests
462 that *oprD* downregulation is a common, and potentially dominant, adaptive *in vivo* trait in chronic *P.*

463 *aeruginosa* infections. Another noteworthy observation is that *in vivo oprD* downregulation was not
464 strictly associated with contemporaneous carbapenem use, as only three of the CF sputa were
465 obtained during carbapenem treatment, and none of the COPD participants had ever received
466 carbapenems. We posit that this adaptive mechanism may provide a rapid, efficient, and effective
467 way for *P. aeruginosa* to evade carbapenems in lieu of encoding functional *oprD* loss. In support of
468 this hypothesis, two prior studies reported decreased *oprD* expression as a cause of carbapenem
469 AMR in 19/33 (58%) (85) and 39/117 (33%) (86) clinical isolates. However, another study showed
470 that *in vitro oprD* downregulation in carbapenem-resistant isolates is a rare event, occurring in just
471 5/40 (13%) isolates (34). As our study illustrates, the markedly different *oprD* expression profiles
472 observed among studies may reflect differing *in vitro* growth conditions; nevertheless, these *in vitro*
473 findings show that *P. aeruginosa* can modulate its *oprD* expression to confer carbapenem AMR. Like
474 *ampC*, our *oprD* results indicate that there may be great clinical value in characterising *in vivo oprD*
475 expression to rapidly identify *P. aeruginosa* infections that are recalcitrant to carbapenem therapy.

476 **Concluding remarks.** Our results add further weight to growing concerns about the relevance of *in*
477 *vitro* AMR research, particularly *in vitro* gene expression analysis, in clinical practice (87, 88). Due to
478 poor correlation between *in vitro* AMR testing and treatment outcomes in CF, empirical antibiotic
479 selection remains the preferred option due to better patient responses (80). Our findings confirm
480 that alternative approaches must be explored that minimise the transcriptional biases introduced
481 during culture (89) to better reflect *in vivo P. aeruginosa* gene expression (87). We recommend that,
482 wherever possible, gene expression of clinical specimens (e.g. sputum) be tested alongside cultured
483 isolates (20). This information will greatly improve our understanding of the shortcomings of *in vitro*
484 AMR testing whilst aiding in clinical decision making, providing more targeted treatment strategies,
485 enhancing antimicrobial stewardship, and improving patient outcomes. Finally, implementation of
486 microbial-enriched metagenomic sequencing of clinical specimens and *in silico* mixture analysis
487 would permit the detection of AMR determinants within a heterogeneous strain population,

488 providing a superior method to culture-based methods for comprehensive AMR determinant
489 identification.

490 **Acknowledgements**

491 This work was supported by Advance Queensland (awards AQIRF0362018 and AQR13016-17RD2),
492 an Australian Government Research Training Program Scholarship, the Wishlist Sunshine Coast
493 Health Foundation (award 2019-14), the IMPACT Philanthropy Application Program
494 (IPAP2016/01112), UQ-QIMRB (Australian Infectious Disease Grant initiative), the National Health
495 and Medical Research Council (award 455919), The Children's Health Foundation Queensland (50 0
496 07), and The Health Innovation, Investment and Research Office of Queensland Health. The funders
497 had no role in study design, data acquisition, analysis, interpretation, writing or submission of the
498 manuscript.

499 References

- 500 1. Alanis AJ. 2005. Resistance to antibiotics: Are we in the post-antibiotic era? *Arch Med Res*
501 36:697-705.
- 502 2. Zhen X, Lundborg CS, Sun X, Hu X, Dong H. 2019. Economic burden of antibiotic resistance in
503 ESKAPE organisms: a systematic review. *Antimicrob Resist Infect Control* 8:137.
- 504 3. Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. 2019. Emerging strategies to
505 combat ESKAPE pathogens in the era of antimicrobial resistance: A review. *Front Microbiol*
506 10:539-539.
- 507 4. Bassetti M, Vena A, Croxatto A, Righi E, Guery B. 2018. How to manage *Pseudomonas*
508 *aeruginosa* infections. *Drugs Context* 7:1-18.
- 509 5. Botelho J, Grosso F, Peixe L. 2019. Antibiotic resistance in *Pseudomonas aeruginosa* -
510 Mechanisms, epidemiology and evolution. *Drug Resist Updat* 44:26-47.
- 511 6. Breidenstein EB, de la Fuente-Nunez C, Hancock RE. 2011. *Pseudomonas aeruginosa*: all
512 roads lead to resistance. *Trends Microbiol* 19:419-26.
- 513 7. Shallcross LJ, Howard SJ, Fowler T, Davies SC. 2015. Tackling the threat of antimicrobial
514 resistance: From policy to sustainable action. *Philos Trans R Soc Lond B Biol Sci* 370:1-5.
- 515 8. O'Neill J. 2014. Antimicrobial resistance: Tackling a crisis for the health and wealth of
516 nations. Accessed 12 August 2021.
- 517 9. Patel A. 2021. Tackling antimicrobial resistance in the shadow of COVID-19. *mBio* 12:1-4.
- 518 10. Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, Vlieghe E, Hara
519 GL, Gould IM, Goossens H, Greko C, So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E,
520 Peralta AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown
521 ED, Cars O. 2013. Antibiotic resistance - the need for global solutions. *Lancet Infect Dis*
522 13:1057-1098.
- 523 11. Su M, Satola SW, Read TD. 2019. Genome-based prediction of bacterial antibiotic resistance.
524 *J Clin Microbiol* 57:1-15.
- 525 12. Rossen JWA, Friedrich AW, Moran-Gilad J. 2018. Practical issues in implementing whole-
526 genome-sequencing in routine diagnostic microbiology. *Clin Microbiol Infect* 24:355-360.
- 527 13. Madden DE, McCarthy KL, Bell SC, Olagoke O, Baird T, Neill J, Ramsay KA, Kidd TJ, Stewart
528 AG, Subedi S, Choong K, Fraser TA, Sarovich DS, Price EP. 2021. Rapid fluoroquinolone
529 resistance detection in *Pseudomonas aeruginosa* using mismatch amplification mutation
530 assay-based real-time PCR. *medRxiv*.
- 531 14. Richardot C, Plesiat P, Fournier D, Monlezun L, Broutin I, Llanes C. 2015. Carbapenem
532 resistance in cystic fibrosis strains of *Pseudomonas aeruginosa* as a result of amino acid
533 substitutions in porin OprD. *Int J Antimicrob Agents* 45:529-32.
- 534 15. Godfroid M, Dagan T, Merker M, Kohl TA, Diel R, Maurer FP, Niemann S, Kupczok A. 2020.
535 Insertion and deletion evolution reflects antibiotics selection pressure in a *Mycobacterium*
536 *tuberculosis* outbreak. *PLoS Pathog* 16:1-24.
- 537 16. Huang TW, Chen TL, Chen YT, Lauderdale TL, Liao TL, Lee YT, Chen CP, Liu YM, Lin AC, Chang
538 YH, Wu KM, Kirby R, Lai JF, Tan MC, Siu LK, Chang CM, Fung CP, Tsai SF. 2013. Copy number
539 change of the NDM-1 sequence in a multidrug-resistant *Klebsiella pneumoniae* clinical
540 isolate. *PLoS One* 8:1-12.
- 541 17. Chalhoub H, Sáenz Y, Rodriguez-Villalobos H, Denis O, Kahl BC, Tulkens PM, Van Bambeke F.
542 2016. High-level resistance to meropenem in clinical isolates of *Pseudomonas aeruginosa* in
543 the absence of carbapenemases: role of active efflux and porin alterations. *Int J Antimicrob*
544 *Agents* 48:740-743.
- 545 18. Stewart AG, Price EP, Schabacker K, Birikmen M, Harris PNA, Choong K, Subedi S, Sarovich
546 DS. 2021. Molecular epidemiology of third-generation cephalosporin-resistant
547 *Enterobacteriaceae* in Southeast Queensland, Australia. *Antimicrob Agents Chemother* 65:1-
548 13.

- 549 19. Chantratita N, Rholl DA, Sim B, Wuthiekanun V, Limmathurotsakul D, Amornchai P,
550 Thanwisai A, Chua HH, Ooi WF, Holden MT, Day NP, Tan P, Schweizer HP, Peacock SJ. 2011.
551 Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in
552 *Burkholderia pseudomallei*. *Proc Natl Acad Sci U S A* 108:17165-70.
- 553 20. Martin LW, Robson CL, Watts AM, Gray AR, Wainwright CE, Bell SC, Ramsay KA, Kidd TJ, Reid
554 DW, Brockway B, Lamont IL. 2018. Expression of *Pseudomonas aeruginosa* antibiotic
555 resistance genes varies greatly during infections in cystic fibrosis patients. *Antimicrob Agents*
556 *Chemother* 62:1-11.
- 557 21. Wheatley R, Diaz Caballero J, Kapel N, de Winter FHR, Jangir P, Quinn A, del Barrio-Tofiño E,
558 López-Causapé C, Hedge J, Torrens G, Van der Schalk T, Xavier BB, Fernández-Cuenca F,
559 Arenzana A, Recanatini C, Timbermont L, Sifakis F, Ruzin A, Ali O, Lammens C, Goossens H,
560 Kluytmans J, Kumar-Singh S, Oliver A, Malhotra-Kumar S, MacLean C. 2021. Rapid evolution
561 and host immunity drive the rise and fall of carbapenem resistance during an acute
562 *Pseudomonas aeruginosa* infection. *Nat Commun* 12:1-12.
- 563 22. Lee JY, Ko KS. 2012. OprD mutations and inactivation, expression of efflux pumps and AmpC,
564 and metallo-beta-lactamases in carbapenem-resistant *Pseudomonas aeruginosa* isolates
565 from South Korea. *Int J Antimicrob Agents* 40:168-72.
- 566 23. Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C,
567 Pena C, Martinez-Martinez L, Oliver A. 2011. Overexpression of *AmpC* and efflux pumps in
568 *Pseudomonas aeruginosa* isolates from bloodstream infections: prevalence and impact on
569 resistance in a Spanish multicenter study. *Antimicrob Agents Chemother* 55:1906-11.
- 570 24. Webb JR, Price EP, Somprasong N, Schweizer HP, Baird RW, Currie BJ, Sarovich DS. 2018.
571 Development and validation of a triplex quantitative real-time PCR assay to detect efflux
572 pump-mediated antibiotic resistance in *Burkholderia pseudomallei*. *Future Microbiol*
573 12:1403-1418.
- 574 25. Poole K. 2011. *Pseudomonas aeruginosa*: Resistance to the max. *Front Microbiol* 2:1-13.
- 575 26. Juan C, Moya B, Perez JL, Oliver A. 2006. Stepwise upregulation of the *Pseudomonas*
576 *aeruginosa* chromosomal cephalosporinase conferring high-level beta-lactam resistance
577 involves three AmpD homologues. *Antimicrob Agents Chemother* 50:1780-7.
- 578 27. Shu JC, Kuo AJ, Su LH, Liu TP, Lee MH, Su IN, Wu TL. 2017. Development of carbapenem
579 resistance in *Pseudomonas aeruginosa* is associated with OprD polymorphisms, particularly
580 the amino acid substitution at codon 170. *J Antimicrob Chemother* 72:2489-2495.
- 581 28. Sherrard LJ, Wee BA, Duplancic C, Ramsay KA, Dave KA, Ballard E, Wainwright CE, Grimwood
582 K, Sidjabat HE, Whiley DM, Beatson SA, Kidd TJ, Bell SC. 2021. Emergence and impact of *oprD*
583 mutations in *Pseudomonas aeruginosa* strains in cystic fibrosis. *J Cyst Fibros* 21:1-9.
- 584 29. Lee JK, Lee YS, Park YK, Kim BS. 2005. Alterations in the GyrA and GyrB subunits of
585 topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-
586 resistant clinical isolates of *Pseudomonas aeruginosa*. *Int J Antimicrob Agents* 25:290-5.
- 587 30. Poole K, Tetro K, Zhao Q, Neshat S, Heinrichs DE, Bianco N. 1996. Expression of the multidrug
588 resistance operon *mexA-mexB-oprM* in *Pseudomonas aeruginosa*: *mexR* encodes a regulator
589 of operon expression. *Antimicrob Agents Chemother* 40:2021-8.
- 590 31. Chen W, Wang D, Zhou W, Sang H, Liu X, Ge Z, Zhang J, Lan L, Yang CG, Chen H. 2016.
591 Novobiocin binding to NalD induces the expression of the MexAB-OprM pump in
592 *Pseudomonas aeruginosa*. *Mol Microbiol* 100:749-58.
- 593 32. Köhler T, Epp SF, Curty LK, Pechère JC. 1999. Characterization of MexT, the regulator of the
594 MexE-MexF-OprN multidrug efflux system of *Pseudomonas aeruginosa*. *J Bacteriol*
595 181:6300-5.
- 596 33. Morita Y, Tomida J, Kawamura Y. 2012. MexXY multidrug efflux system of *Pseudomonas*
597 *aeruginosa*. *Front Microbiol* 3:1-13.
- 598 34. Aghazadeh M, Hojabri Z, Mahdian R, Nahaei MR, Rahmati M, Hojabri T, Pirzadeh T, Pajand O.
599 2014. Role of efflux pumps: MexAB-OprM and MexXY(-OprA), AmpC cephalosporinase and

- 600 OprD porin in non-metallo-beta-lactamase producing *Pseudomonas aeruginosa* isolated
601 from cystic fibrosis and burn patients. *Infect Genet Evol* 24:187-92.
- 602 35. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ,
603 Nishino T. 1996. Overexpression of the *mexC-mexD-oprJ* efflux operon in *nfxB*-type
604 multidrug-resistant strains of *Pseudomonas aeruginosa*. *Mol Microbiol* 21:713-24.
- 605 36. Fraud S, Campigotto AJ, Chen Z, Poole K. 2008. MexCD-OprJ multidrug efflux system of
606 *Pseudomonas aeruginosa*: Involvement in chlorhexidine resistance and induction by
607 membrane-damaging agents dependent upon the AlgU stress response sigma factor.
608 *Antimicrob Agents Chemother* 52:4478-4482.
- 609 37. Gotoh N, Tsujimoto H, Tsuda M, Okamoto K, Nomura A, Wada T, Nakahashi M, Nishino T.
610 1998. Characterization of the MexC-MexD-OprJ Multidrug Efflux System in *mexA-mexB-*
611 *oprM* Mutants of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 42:1938-1943.
- 612 38. Oh H, Stenhoff J, Jalal S, Wretling B. 2003. Role of efflux pumps and mutations in genes for
613 topoisomerases II and IV in fluoroquinolone-resistant *Pseudomonas aeruginosa* strains.
614 *Microb Drug Resist* 9:323-8.
- 615 39. Islam S, Jalal S, Wretling B. 2004. Expression of the MexXY efflux pump in amikacin-resistant
616 isolates of *Pseudomonas aeruginosa*. *Clin Microbiol Infect* 10:877-83.
- 617 40. Webb KA, Olagoke O, Baird T, Neill J, Pham A, Wells TJ, Ramsay KA, Bell SC, Sarovich DS,
618 Price EP. 2021. Genomic diversity and antimicrobial resistance of *Prevotella* spp. isolated
619 from chronic lung disease airways. *Microb Genom* 8:000754.
- 620 41. Nadkarni MA, Martin FE, Jacques NA, Hunter N. 2002. Determination of bacterial load by
621 real-time PCR using a broad-range (universal) probe and primers set. *Microbiology (Reading)*
622 148:257-266.
- 623 42. de Lamballerie X, Zandotti C, Vignoli C, Bollet C, de Micco P. 1992. A one-step microbial DNA
624 extraction method using "Chelex 100" suitable for gene amplification. *Res Microbiol*
625 143:785-90.
- 626 43. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP. 2009.
627 Identification of *Pseudomonas aeruginosa* by a duplex real-time polymerase chain reaction
628 assay targeting the *ecfX* and the *gyrB* genes. *Diagn Microbiol Infect Dis* 63:127-31.
- 629 44. Horcajada JP, Montero M, Oliver A, Sorlí L, Luque S, Gómez-Zorrilla S, Benito N, Grau S. 2019.
630 Epidemiology and treatment of multidrug-resistant and extensively drug-resistant
631 *Pseudomonas aeruginosa* infections. *Clin Microbiol Rev* 32:1-52.
- 632 45. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. 2000. Substrate
633 specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in *Pseudomonas*
634 *aeruginosa*. *Antimicrob Agents Chemother* 44:3322-7.
- 635 46. Buffet-Bataillon S, Tattevin P, Maillard J-Y, Bonnaure-Mallet M, Jolivet-Gougeon A. 2016.
636 Efflux pump induction by quaternary ammonium compounds and fluoroquinolone resistance
637 in bacteria. *Future Microbiol* 11:81-92.
- 638 47. Fetar H, Gilmour C, Klinoski R, Daigle DM, Dean CR, Poole K. 2011. *mexEF-oprN* multidrug
639 efflux operon of *Pseudomonas aeruginosa*: Regulation by the MexT activator in response to
640 nitrosative stress and chloramphenicol. *Antimicrob Agents Chemother* 55:508-514.
- 641 48. Dunne WM, Jr., Hardin DJ. 2005. Use of several inducer and substrate antibiotic
642 combinations in a disk approximation assay format to screen for AmpC induction in patient
643 isolates of *Pseudomonas aeruginosa*, *Enterobacter* spp., *Citrobacter* spp., and *Serratia* spp. *J*
644 *of Clin Microbiol* 43:5945-5949.
- 645 49. Oliver A, Baquero F, Blázquez J. 2002. The mismatch repair system (*mutS*, *mutL* and *uvrD*
646 genes) in *Pseudomonas aeruginosa*: Molecular characterization of naturally occurring
647 mutants. *Mol Microbiol* 43:1641-1650.
- 648 50. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras J-B, Barbu EM, Shortridge D, Blanc
649 B, Hannum G, Zambardi G, Miller K, Enright MC, Mugnier N, Bami D, Schicklin S, Felderman
650 M, Schwartz AS, Richardson TH, Peterson TC, Hubby B, Cady KC. 2015. Phylogenetic


- 651 distribution of CRISPR-Cas systems in antibiotic-resistant *Pseudomonas aeruginosa*. *mBio*
652 6:1-13.
- 653 51. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MÁ, Zamorano L,
654 Juan C, Tubau F, Rodríguez C, Moyà B, Peña C, Martínez-Martínez L, Plesiat P, Oliver A. 2016.
655 Deciphering the resistome of the widespread *Pseudomonas aeruginosa* sequence type 175
656 international high-risk clone through whole-genome sequencing. *Antimicrob Agents*
657 *Chemother* 60:7415-7423.
- 658 52. Kos VN, Déraspe M, McLaughlin RE, Whiteaker JD, Roy PH, Alm RA, Corbeil J, Gardner H.
659 2015. The resistome of *Pseudomonas aeruginosa* in relationship to phenotypic susceptibility.
660 *Antimicrob Agents Chemother* 59:427-436.
- 661 53. Del Barrio-Tofiño E, López-Causapé C, Cabot G, Rivera A, Benito N, Segura C, Montero MM,
662 Sorlí L, Tubau F, Gómez-Zorrilla S, Tormo N, Durá-Navarro R, Viedma E, Resino-Foz E,
663 Fernández-Martínez M, González-Rico C, Alejo-Cancho I, Martínez JA, Labayru-Echverria C,
664 Dueñas C, Ayestarán I, Zamorano L, Martínez-Martínez L, Horcajada JP, Oliver A. 2017.
665 Genomics and susceptibility profiles of extensively drug-resistant *Pseudomonas aeruginosa*
666 isolates from Spain. *Antimicrob Agents Chemother* 61:1-13.
- 667 54. Sherrard LJ, Tai AS, Wee BA, Ramsay KA, Kidd TJ, Ben Zakour NL, Whiley DM, Beatson SA,
668 Bell SC. 2017. Within-host whole genome analysis of an antibiotic resistant *Pseudomonas*
669 *aeruginosa* strain sub-type in cystic fibrosis. *PLoS ONE* 12:1-15.
- 670 55. Fraser TA, Bell MG, Harris PNA, Bell SC, Bergh H, Nguyen T-K, Kidd TJ, Nimmo GR, Sarovich
671 DS, Price EP. 2019. Quantitative real-time PCR assay for the rapid identification of the
672 intrinsically multidrug-resistant bacterial pathogen *Stenotrophomonas maltophilia*. *Microb*
673 *Genom* 5:2-11.
- 674 56. Price EP, Dale JL, Cook JM, Sarovich DS, Seymour ML, Ginther JL, Kaufman EL, Beckstrom-
675 Sternberg SM, Mayo M, Kaestli M, Glass MB, Gee JE, Wuthiekanun V, Warner JM, Baker A,
676 Foster JT, Tan P, Tuanyok A, Limmathurotsakul D, Peacock SJ, Currie BJ, Wagner DM, Keim P,
677 Pearson T. 2012. Development and validation of *Burkholderia pseudomallei*-specific real-
678 time PCR assays for clinical, environmental or forensic detection applications. *PLoS One* 7:1-
679 9.
- 680 57. Araujo P. 2009. Key aspects of analytical method validation and linearity evaluation. *J*
681 *Chromatogr B Analyt Technol Biomed Life Sci* 877:2224-34.
- 682 58. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time
683 quantitative PCR and the 2⁻(Delta Delta C(T)) Method. *Methods* 25:402-8.
- 684 59. Madden DE, Webb JR, Steinig EJ, Currie BJ, Price EP, Sarovich DS. 2021. Taking the next-gen
685 step: Comprehensive antimicrobial resistance detection from *Burkholderia pseudomallei*.
686 *EBioMedicine* 63:103152.
- 687 60. Wood DE, Lu J, Langmead B. 2019. Improved metagenomic analysis with Kraken 2. *Genome*
688 *Biol* 20:257.
- 689 61. Pedersen BS, Quinlan AR. 2018. Mosdepth: quick coverage calculation for genomes and
690 exomes. *Bioinformatics* 34:867-868.
- 691 62. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe RL,
692 Rebelo AR, Florensa AF, Fagelhauer L, Chakraborty T, Neumann B, Werner G, Bender JK,
693 Stingl K, Nguyen M, Coppens J, Xavier BB, Malhotra-Kumar S, Westh H, Pinholt M, Anjum
694 MF, Duggett NA, Kempf I, Nykäsenoja S, Olkkola S, Wiczorek K, Amaro A, Clemente L,
695 Mossong J, Losch S, Ragimbeau C, Lund O, Aarestrup FM. 2020. ResFinder 4.0 for predictions
696 of phenotypes from genotypes. *Journal of Antimicrobial Chemotherapy* 75:3491-3500.
- 697 63. Juan C, Macia MD, Gutierrez O, Vidal C, Perez JL, Oliver A. 2005. Molecular mechanisms of β -
698 lactam resistance mediated by AmpC hyperproduction in *Pseudomonas aeruginosa* clinical
699 strains. *Antimicrob Agents Chemother* 49:4733-8.
- 700 64. Kong KF, Aguila A, Schnepfer L, Mathee K. 2010. *Pseudomonas aeruginosa* beta-lactamase
701 induction requires two permeases, AmpG and AmpP. *BMC Microbiol* 10:328.

- 702 65. Tomás M, Doumith M, Warner M, Turton JF, Beceiro A, Bou G, Livermore DM, Woodford N.
703 2010. Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in *Pseudomonas*
704 *aeruginosa* isolates from cystic fibrosis patients. *Antimicrob Agents Chemother* 54:2219-24.
- 705 66. Purssell A, Poole K. 2013. Functional characterization of the NfxB repressor of the *mexCD-*
706 *oprJ* multidrug efflux operon of *Pseudomonas aeruginosa*. *Microbiology (Reading)* 159:2058-
707 2073.
- 708 67. Livermore DM. 1995. Beta-Lactamases in laboratory and clinical resistance. *Clin Microbiol*
709 *Rev* 8:557-84.
- 710 68. Rehman A, Jeukens J, Levesque RC, Lamont IL. 2021. Gene-gene interactions dictate
711 ciprofloxacin resistance in *Pseudomonas aeruginosa* and facilitate prediction of resistance
712 phenotype from genome sequence data. *Antimicrob Agents Chemother* 65:1-15.
- 713 69. Clark ST, Sinha U, Zhang Y, Wang PW, Donaldson SL, Coburn B, Waters VJ, Yau YCW, Tullis
714 DE, Guttman DS, Hwang DM. 2019. Penicillin-binding protein 3 is a common adaptive target
715 among *Pseudomonas aeruginosa* isolates from adult cystic fibrosis patients treated with β -
716 lactams. *Int J Antimicrob Agents* 53:620-628.
- 717 70. Bolard A, Plésiat P, Jeannot K. 2018. Mutations in gene *fusA1* as a novel mechanism of
718 aminoglycoside resistance in clinical strains of *Pseudomonas aeruginosa*. *Antimicrob Agents*
719 *Chemother* 62:1-10.
- 720 71. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC. 1997.
721 Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of
722 *Pseudomonas aeruginosa*. *Mol Microbiol* 23:345-54.
- 723 72. Feng X, Zhang Z, Li X, Song Y, Kang J, Yin D, Gao Y, Shi N, Duan J. 2019. Mutations in *gyrB* play
724 an important role in ciprofloxacin-resistant *Pseudomonas aeruginosa*. *Infect Drug Resist*
725 12:261-272.
- 726 73. Higgins PG, Fluit AC, Milatovic D, Verhoef J, Schmitz FJ. 2003. Mutations in *GyrA*, *ParC*, *MexR*
727 and *NfxB* in clinical isolates of *Pseudomonas aeruginosa*. *Int J Antimicrob Agents* 21:409-13.
- 728 74. Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S. 2009. Genomewide
729 identification of genetic determinants of antimicrobial drug resistance in *Pseudomonas*
730 *aeruginosa*. *Antimicrob Agents Chemother* 53:2522-31.
- 731 75. Colque CA, Albarracín Orió AG, Feliziani S, Marvig RL, Tobares AR, Johansen HK, Molin S,
732 Smania AM. 2020. Hypermutator *Pseudomonas aeruginosa* Exploits Multiple Genetic
733 Pathways To Develop Multidrug Resistance during Long-Term Infections in the Airways of
734 Cystic Fibrosis Patients. *Antimicrob Agents Chemother* 64.
- 735 76. Zamorano L, Moya B, Juan C, Oliver A. 2010. Differential beta-lactam resistance response
736 driven by *ampD* or *dacB* (PBP4) inactivation in genetically diverse *Pseudomonas aeruginosa*
737 strains. *J Antimicrob Chemother* 65:1540-2.
- 738 77. Winstanley C, O'Brien S, Brockhurst MA. 2016. *Pseudomonas aeruginosa* evolutionary
739 adaptation and diversification in cystic fibrosis chronic lung infections. *Trends Microbiol*
740 24:327-337.
- 741 78. Valderrey AD, Pozuelo MJ, Jiménez PA, Maciá MD, Oliver A, Rotger R. 2010. Chronic
742 colonization by *Pseudomonas aeruginosa* of patients with obstructive lung diseases: cystic
743 fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. *Diagn Microbiol Infect*
744 *Dis* 68:20-7.
- 745 79. Lee M, Hesek D, Blázquez B, Lastochkin E, Boggess B, Fisher JF, Mobashery S. 2015. Catalytic
746 spectrum of the penicillin-binding protein 4 of *Pseudomonas aeruginosa*, a nexus for the
747 induction of β -lactam antibiotic resistance. *J Am Chem Soc* 137:190-200.
- 748 80. Van den Bossche S, De Broe E, Coenye T, Van Braeckel E, Crabbé A. 2021. The cystic fibrosis
749 lung microenvironment alters antibiotic activity: Causes and effects. *Eur Respir Rev* 30:1-16.
- 750 81. Vettoretti L, Plesiat P, Muller C, El Garch F, Phan G, Attree I, Ducruix A, Llanes C. 2009. Efflux
751 unbalance in *Pseudomonas aeruginosa* isolates from cystic fibrosis patients. *Antimicrob*
752 *Agents Chemother* 53:1987-97.

- 753 82. Goodman AL, Kulasekara B, Rietsch A, Boyd D, Smith RS, Lory S. 2004. A signaling network
754 reciprocally regulates genes associated with acute infection and chronic persistence in
755 *Pseudomonas aeruginosa*. *Dev Cell* 7:745-54.
- 756 83. Werner E, Roe F, Bugnicourt A, Franklin MJ, Heydorn A, Molin S, Pitts B, Stewart PS. 2004.
757 Stratified growth in *Pseudomonas aeruginosa* biofilms. *Appl Environ Microbiol* 70:6188-96.
- 758 84. Murphy TF. 2008. The many faces of *Pseudomonas aeruginosa* in chronic obstructive
759 pulmonary disease. *Clin Infect Dis* 47:1534-1536.
- 760 85. Quale J, Bratu S, Gupta J, Landman D. 2006. Interplay of efflux system, *ampC*, and *oprD*
761 expression in carbapenem resistance of *Pseudomonas aeruginosa* clinical isolates.
762 *Antimicrob Agents Chemother* 50:1633-1641.
- 763 86. Pai H, Kim J, Kim J, Lee JH, Choe KW, Gotoh N. 2001. Carbapenem resistance mechanisms in
764 *Pseudomonas aeruginosa* clinical isolates. *Antimicrob Agents Chemother* 45:480-4.
- 765 87. Fung C, Naughton S, Turnbull L, Tingpej P, Rose B, Arthur J, Hu H, Harmer C, Harbour C,
766 Hassett DJ, Whitchurch CB, Manos J. 2010. Gene expression of *Pseudomonas aeruginosa* in a
767 mucin-containing synthetic growth medium mimicking cystic fibrosis lung sputum. *J Med*
768 *Microbiol* 59:1089-1100.
- 769 88. Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S, Elkins M, Thompson B, MacLeod C, Aaron
770 SD, Harbour C. 2005. Antibiotic susceptibilities of *Pseudomonas aeruginosa* isolates derived
771 from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. *J of Clin*
772 *Microbiol* 43:5085-5090.
- 773 89. Kirchner S, Fothergill JL, Wright EA, James CE, Mowat E, Winstanley C. 2012. Use of artificial
774 sputum medium to test antibiotic efficacy against *Pseudomonas aeruginosa* in conditions
775 more relevant to the cystic fibrosis lung. *J Vis Exp* 64:1-7.

776


777 Figures



778

779 **Figure 1.** *In vivo* expression of *Pseudomonas aeruginosa* antimicrobial resistance loci in six cystic
780 fibrosis (CF) and five chronic obstructive pulmonary disease (COPD) sputa. Gene expression for each
781 sample at each locus was first normalised against *rpsL* (ΔC_T); relative log₂ fold-change expression was
782 then determined by comparing ΔC_T values against COPD participant SCHI0070 (i.e. $\Delta\Delta C_T$), who was
783 not receiving anti-pseudomonal antibiotics at the time of sputum collection. For SCHI0030, in which
784 longitudinal sputa over antibiotic treatment were obtained, only the Day 0 sputum was used in this
785 analysis to ensure independence of all observations. *, adjusted $p < 0.05$; **, adjusted $p < 0.01$; ***,
786 adjusted $p < 0.001$; ns, not significant. Error bars=95% confidence interval.

787



788

789 **Figure 2.** Differential expression (relative log₂ fold change) of *Pseudomonas aeruginosa* antimicrobial
790 resistance loci in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) sputa. Gene
791 expression for each locus was first normalised against *rpsL* (ΔC_T); relative expression was then
792 determined by comparing ΔC_T values against sputum from COPD participant SCHI0070 (i.e. $\Delta\Delta C_T$),
793 who was not receiving anti-pseudomonal antibiotics at the time of sputum collection. For
794 participants receiving anti-pseudomonal antibiotics, sputa are denoted by 'Day post-antibiotics' (D)
795 (see Table 1 for details). Error bars, standard deviation. †Participants receiving non-pseudomonal
796 antibiotics at the time of sputum collection.

797 **Tables**

798 **Table 1.** *Pseudomonas aeruginosa*-positive sputa, corresponding derived isolates, disc diffusion profiles across 11 anti-pseudomonal antibiotics, and
 799 predicted antimicrobial resistance (AMR) phenotypes from whole-genome sequencing (WGS) and culturomic data.

Disease	Sputum ID [†]	Derived isolate ID	Aminoglycosides		Penicillins		Cephalosporins		FQs	Polymyxins		Carbapenems		Treatment	WGS variants (AMR phenotype)	Culturomic variants (AMR phenotype; proportion identified)
			AMK	TOB	PIP	TZP	CAZ	FEP	CIP	CST	PMB	IPM	MEM [#]			
CF	SCHI0002 (Day 8)	SCHI0002.S.8	S	S	R	I	I	R	I	S	S	R	S	IV CAZ, MEM, TOB	GyrB S466F (CIPi); OprD W339Ter (MEMr, IPMr); FtsI R504C (MEMr, IPMr, CAZr; FEP, TZPr, PIPr)	NaID D187H (100%), PA1259 F273fs (PIP; 38%), PA3127 loss (100%), GyrB E483D (CIPi; 8%), ParC S87W (CIP; 10%), PA2198 R33fs (PIP; 11%), PepA E363fs (PIP; 14%), FdnH V215fs (PIP; 12%)
		SCHI0002.S.9	R	S	R	R	R	R	I	S	S	R	R	IV CAZ, MEM, TOB	NaID D187H (CIPi, FEPi, CAZi, MEMi, IPMi); PA3127 loss (PIP)	
	SCHI0002 (Day 329)	SCHI0002.S.12	R	R	R	R	R	R	I	S	S	S	S	IV CAZ, MEM, TOB	NaID D187H (CIPi, FEPi, CAZi, MEMi, IPMi); PA2326 loss (PIP, FEP); PA3127 loss (PIP)	NaID D187H (100%)
	SCHI0010 (Day 7)	SCHI0010.S.1	R	R	R	R	R	R	R	S	S	R	R	IV CAZ, TOB	FusA1 A555E (AMKr, TOBr); GyrA T83I (CIPr); PA2693 D17fs (PIP, TZPr, MEMr, FEP, CAZr); PA2531 A137fs (PIP); PckA G418fs (PIP); <i>aac(6)-IIa</i> (TOBr)	FtsI H394R (61%), FusA1 A555E (100%), GyrA T83I (100%), PA2693 D17fs (100%), PA2531 A137fs (78%)
	SCHI0013 (Day 4)	SCHI0013.S.2	S	R	S	S	S	I	S	S	S	R	S	IV FOF, MEM	GyrB S466Y (CIPi), ParE A473V (CIPi), PA1942 loss (PIP), MexE R229fs (CIPs); <i>ant(2'')-Ia</i> (TOBr)	OprD W6Ter (IPMr, MEMr; 22%), GyrB S466Y (96%), PA1942 loss (51%), PA3093 loss (PIP; 15%), MexE R229fs (100%)
		SCHI0013.S.12	R	S	R	S	S	R	I	S	S	R	I	IV FOF, MEM	GyrB S466Y (CIPi); ParE A473V (CIPi); MexE R229fs (CIPs)	

	SCHI0018 (Day 8)	SCHI0018.S.11	S	R	R	I	R	I	S	S	S	S	---	IV CAZ, TZP, TOB	Not sequenced	ND
	SCHI0030 (Day 0)	SCHI0030.S.1	S	S	S	S	S	I	S	S	S	S	S	Nil	None	ND
	SCHI0030 (Day 6)	SCHI0030.S.2	R	R	R	R	R	R	I	S	S	R	R	IV ATM, TOB	PA1821 loss (PIPr, TZPr); MexF Y37Ter (CIPs); AmpD P42fs (CAZi, PIPi, TZPi, FEPi, IPMi, MEMi); FtsI R504C (MEMr, IPMr, CAZr, FEPr, TZPr, PIPr); GyrA D87H (CIPr)	ND
	SCHI0030 (Day 13)	SCHI0030.S.3	R	I	R	R	R	R	R	S	S	R	R	IV ATM, TOB	AmpD P42fs (CAZi, PIPi, TZPi, FEPi, MEMi, IPMi); OprD G193fs (MEMr, IPMr); MexF Y37Ter (CIPs); FtsI R504C (MEMr, IPMr, CAZr, FEPr, TZPr, PIPr); GyrA D87H (CIPr)	ND
	SCHI0030 (Day 50)*	SCHI0030.S.4	R	R	R	R	R	R	R	S	S	R	R	Nil	NfxB F126fs (CIPr, FEPr)	ND
		SCHI0030.S.5	S	S	S	S	S	S	S	S	S	S	S	Nil	None	
COPD	SCHI0038*	SCHI0038.S.2	I	R	S	S	S	S	S	S	S	S	S	Nil	Not sequenced	AmpG E592fs (100%)
		SCHI0038.S.3	S	S	S	S	S	S	S	S	S	S	S	Nil	AmpG E592fs (CAZs, FEPs, PIPs, TZPs)	
		SCHI0038.S.4	S	I	S	S	S	S	S	S	S	S	S	Nil	Not sequenced	
	SCHI0039*	SCHI0039.S.1	S	S	S	S	S	S	S	S	S	S	S	Nil	PA0090 R532_E535delinsQ (TZPr, FEPr, PIPr)	None
	SCHI0050 (Day 3)	SCHI0050.S.1	S	S	S	S	S	S	S	S	S	S	S	Oral CIP	ParC Q405R (precursor; causes CIPr in combination with a <i>gyrA</i> mutation)	ParC Q405R (100%)
	SCHI0065*	SCHI0065.S.1	S	S	S	S	S	S	S	S	S	S	S	Oral AZM	None	ND
	SCHI0070 (Day 2)*	SCHI0070.S.1	S	S	S	S	S	S	S	S	S	S	S	Oral AMC	None	ND
	SCHI0109	Not retrieved	---	---	---	---	---	---	---	---	---	---	---	Oral CIP and AZM; azathioprine	---	ND
Control	---	PAO1	S	S	S	S	S	S	S	S	S	S	S	---	None	NA

800 Abbreviations: AMK, amikacin; AMR, antimicrobial resistance; ATM, aztreonam; AZM, azithromycin; CAZ, ceftazidime; cDNA, complementary DNA; CF,
801 cystic fibrosis; CIP, ciprofloxacin; CST, colistin; COPD, chronic obstructive pulmonary disease; FEP, cefepime; FOF, fosfomicin; FQ, fluoroquinolones; fs,

802 frameshift; I or i, intermediate resistance; IPM, imipenem; MEM, meropenem; PMB, polymyxin B; PIP, piperacillin; R or r, antimicrobial resistant; S or s,
803 antimicrobial sensitive; TZP, piperacillin/tazobactam; TOB, tobramycin; AZM, azithromycin; AMC, amoxicillin/clavulanic acid

804 †Days since commencing antibiotics

805 *Not receiving anti-pseudomonal antibiotics at time of sputum collection

806 #MEM antibiotic resistance profiles were determined using E-TESTs

807

808 **Table 2.** Primers and probes designed in this study.

Multiplex	Gene target	AMR target	Fluorophore	Oligo name	Oligo sequence (5'-3')	Optimised concentration (μ M)
1	mexY	RND efflux pump	HEX	mexY-For	AAGAGGACCAGGGCGACTTC	0.20
				mexY-Rev	CTTCAGGGTGGCGAAGATCAT	0.20
				mexY-Probe	TGAAGCCGCCGACCGCA	0.20
	mexB	RND efflux pump	FAM	mexB-For	ACCGTGGTCCAGGTGATCG	0.15
				mexB-Rev	AGTTACTCTCCGAGGAGATGTAGCG	0.15
				mexB-Probe	CAGCAGATGAACGGGATCG	0.20
	ampC	β -lactamase	Texas Red	ampC-For	CTTCGACGGCATCAGCCT	0.45
				ampC-Rev	CCGATGCTCGGGTTGGA	0.45
				ampC-Probe	CAGATCCGCGACTACTACCGCCAGTG	0.20
	rpsL	Housekeeping gene	Cy5	rpsL-For	CGACAAGAGCGACGTGCC	0.25
				rpsL-Rev	TTACGCAGTGCCGAGTTTCG	0.25
				rpsL-Probe	CATACGCCACGACGTTGCG	0.20
2	mexC	RND efflux pump	HEX	mexC-For	GTGCTGTTTCGAGGCGCAG	0.20
				mexC-Rev	TCCTGCTGGCTGACCGC	0.20
				mexC-Probe	CTGGATCTTCACCAGCGGCT	0.25
	oprD	Porin	FAM	oprD-For	AAGTGGAGCGCCATTGCA	0.20
				oprD-Rev	TAGTAGTTGCGGAGCAGCAGGT	0.20
				oprD-Probe	CTGCTGTCTTCGATGAACC	0.20
	mexE	RND efflux pump	Texas Red	mexE-For	TACCTCGGCCTGAGCAGC	0.25
				mexE-Rev	GTTGACCTGGTTGTCGAGGAAG	0.25
				mexE-Probe	ACGGCAACCCGCACCTG	0.30

809 Abbreviations: AMR, antimicrobial resistant (allele); cDNA, complementary DNA; RND, resistance-

810 nodulation-division; SNP, single-nucleotide polymorphism; WT, wild-type (allele)

811 *Bolded nucleotides indicate the SNP; underlined nucleotides indicate deliberately incorporated

812 antepenultimate/penultimate mismatches to enhance allele specificity